
<!DOCTYPE html>
<html lang="en">
<head>
    <meta charset="UTF-8">
    <title>Document Content</title>
    <style>
        body { font-family: Arial, sans-serif; line-height: 1.6; max-width: 900px; margin: auto; padding: 20px; }
        table { border-collapse: collapse; width: 100%; margin-top: 20px; margin-bottom: 20px; }
        th, td { border: 1px solid #cccccc; text-align: left; padding: 8px; font-size: 12px; }
        tr:nth-child(even) { background-color: #f9f9f9; }
        th { background-color: #3366CC; color: white; font-weight: bold; }
        h2 { color: #4F81BD; border-bottom: 2px solid #4F81BD; padding-bottom: 5px;}
        p { margin-block-start: 0.5em; margin-block-end: 0.5em; }
    </style>
</head>
<body>
    <p style="font-size: small; color: grey;"><i>Page 48 of 88</i></p>
<p style="font-size: small; color: grey;"><i>acad-10k 20171231.htm</i></p>
<p style="font-size: small; color: grey;"><i>ACADIA_PHARMACEUTICALS_10k_048.pdf</i></p>
<h2>Item 6. Selected Financial Data.</h2>
<p>The following data has been derived from our audited financial statements, including the consolidated balance sheets at December 31, 2017 and 2016 and the related consolidated statements of operations for each of the three years ended December 31, 2017 and related notes appearing elsewhere in this report. The consolidated statement of operations data for the years ended December 31, 2014 and 2013 and the consolidated balance sheet data as of December 31, 2015, 2014 and 2013 are derived from our audited consolidated financial statements that are not included in this report. You should read the selected financial data set forth below in conjunction with &quot;Management&#x27;s Discussion and Analysis of Financial Condition and Results of Operations&quot; and our consolidated financial statements and related notes included elsewhere in this report.</p>

<table>
	<tr>
		<th rowspan="2"></th>
		<th colspan="5">Years Ended December 31,</th>
	</tr>
	<tr>
		<th>2017</th>
		<th>2016</th>
		<th>2015</th>
		<th>2014</th>
		<th>2013</th>
	</tr>
	<tr>
		<td></td>
		<td colspan="5">(in thousands, except per share amounts)</td>
	</tr>
	<tr>
		<td>Consolidated Statement of Operations Data:</td>
		<td></td>
		<td></td>
		<td></td>
		<td></td>
		<td></td>
	</tr>
	<tr>
		<td>Revenues:</td>
		<td></td>
		<td></td>
		<td></td>
		<td></td>
		<td></td>
	</tr>
	<tr>
		<td>Product sales, net</td>
		<td>$ 124,901</td>
		<td>$ 17,327</td>
		<td>$ —</td>
		<td>$ —</td>
		<td>$ —</td>
	</tr>
	<tr>
		<td>Collaborative revenue</td>
		<td>—</td>
		<td>4</td>
		<td>61</td>
		<td>120</td>
		<td>1,145</td>
	</tr>
	<tr>
		<td>Total revenues</td>
		<td>124,901</td>
		<td>17,331</td>
		<td>61</td>
		<td>120</td>
		<td>1,145</td>
	</tr>
	<tr>
		<td>Operating expenses:</td>
		<td></td>
		<td></td>
		<td></td>
		<td></td>
		<td></td>
	</tr>
	<tr>
		<td>Cost of product sales</td>
		<td>9,077</td>
		<td>3,075</td>
		<td>—</td>
		<td>—</td>
		<td>—</td>
	</tr>
	<tr>
		<td>License fees and royalties</td>
		<td>3,983</td>
		<td>1,331</td>
		<td>2,500</td>
		<td>—
</td>
		<td>—
</td>
	</tr>
	<tr>
		<td>Research and development</td>
		<td>149,189</td>
		<td>99,284</td>
		<td>73,869</td>
		<td>60,602</td>
		<td>26,722</td>
	</tr>
	<tr>
		<td>Selling, general and administrative</td>
		<td>255,062</td>
		<td>186,456</td>
		<td>88,304</td>
		<td>32,748</td>
		<td>12,720</td>
	</tr>
	<tr>
		<td>Total operating expenses</td>
		<td>417,311</td>
		<td>290,146</td>
		<td>164,673</td>
		<td>93,350</td>
		<td>39,442</td>
	</tr>
	<tr>
		<td>Loss from operations</td>
		<td>(292,410)</td>
		<td>(272,815)</td>
		<td>(164,612)</td>
		<td>(93,230)</td>
		<td>(38,297)</td>
	</tr>
	<tr>
		<td>Interest income, net</td>
		<td>4,126</td>
		<td>2,763</td>
		<td>499</td>
		<td>755</td>
		<td>349</td>
	</tr>
	<tr>
		<td>Loss before income taxes</td>
		<td>(288,284)</td>
		<td>(270,052)</td>
		<td>(164,113)</td>
		<td>(92,475)</td>
		<td>(37,948)</td>
	</tr>
	<tr>
		<td>Income tax expense</td>
		<td>1,119</td>
		<td>1,341</td>
		<td>330</td>
		<td>—</td>
		<td>—</td>
	</tr>
	<tr>
		<td>Net loss</td>
		<td>$ (289,403)</td>
		<td>$ (271,393)</td>
		<td>$ (164,443</td>
		<td>$ (92,475)</td>
		<td>$ (37,948)</td>
	</tr>
	<tr>
		<td>Net loss per common share, basic and diluted</td>
		<td>$ (2.36)</td>
		<td>$ (2.34)</td>
		<td>$ (1.63)</td>
		<td>$ (0.95)</td>
		<td>$ (0.44)</td>
	</tr>
	<tr>
		<td>Weighted average common shares outstanding, basic and diluted</td>
		<td>122,600</td>
		<td>115,858</td>
		<td>100,630</td>
		<td>97,248</td>
		<td>85,715</td>
	</tr>
</table>

<table>
	<tr>
		<th rowspan="2"></th>
		<th colspan="5">At December 31,</th>
	</tr>
	<tr>
		<th>2017</th>
		<th>2016</th>
		<th>2015</th>
		<th>2014</th>
		<th>2013</th>
	</tr>
	<tr>
		<td></td>
		<td colspan="5">(in thousands)</td>
	</tr>
	<tr>
		<td>Consolidated Balance Sheet Data:</td>
		<td></td>
		<td></td>
		<td></td>
		<td></td>
		<td></td>
	</tr>
	<tr>
		<td>Cash, cash equivalents and investment securities</td>
		<td>$ 341,342</td>
		<td>$ 529,036</td>
		<td>$ 215,132</td>
		<td>$ 322,486</td>
		<td>$ 185,790</td>
	</tr>
	<tr>
		<td>Working capital</td>
		<td>324,447</td>
		<td>505,312</td>
		<td>197,087</td>
		<td>308,784</td>
		<td>181,381</td>
	</tr>
	<tr>
		<td>Total assets</td>
		<td>384,506</td>
		<td>561,153</td>
		<td>221,896</td>
		<td>325,458</td>
		<td>189,118</td>
	</tr>
	<tr>
		<td>Total stockholders&#x27; equity</td>
		<td>335,285</td>
		<td>518,411</td>
		<td>199,762</td>
		<td>309,489</td>
		<td>182,131</td>
	</tr>
</table>
<p style="font-size: small; color: grey;"><i>46</i></p>
<p style="font-size: small; color: grey;"><i>file://usmdcvdi003.us.kworld.kpmg.com/GDC_Ops/Operations/Gayathri%20Krishnan/RPA%20Phase%20II/Kiran/HealthCare/ ... 7/23/2018</i></p>

</body>
</html>
